Intravesicular Onabotulinumtoxin A Hemorrhage on Rivaroxaban
نویسندگان
چکیده
منابع مشابه
A Case of Rivaroxaban Associated Intracranial Hemorrhage
Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first case reports of severe intracranial hemorrhage associated with rivaroxaban in an elderly patient ...
متن کاملIntracranial Hemorrhage in Patient Treated with Rivaroxaban
Rivaroxaban is an oral factor Xa inhibitor used for stroke prevention in atrial fibrillation. There are currently no evidence-based guidelines for the treatment of hemorrhagic side effects of factor Xa inhibitors. We report a case of a thalamic hemorrhage in an 84 year-old right-handed female on rivaroxaban for treatment of atrial fibrillation. The patient had fallen down steps and became unres...
متن کاملCharacteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment
Novel oral anticoagulants (NOACs) reduce incidence of stroke and intracerebral hemorrhage (ICH) in patients with nonvalvular atrial fibrillation. Several studies demonstrated hematoma expansion in patients with ICH occurring during warfarin therapy and poor clinical outcomes. However, information regarding hematoma size, its expansion, and functional and vital outcomes of patients with ICH occu...
متن کاملNon-hemorrhage-related adverse effects of rivaroxaban
The direct oral anticoagulant rivaroxaban is useful in various indications that include venous deep vein thrombosis prophylaxis/treatment after knee/hip replacement surgery and prevention of stroke in patients with non-valvular atrial fibrillation. Its mechanism of action has been mostly associated with hemorrhage-related adverse effects; thus a number of non-hemorrhage-related adverse effects ...
متن کاملA rare complication in a patient taking rivaroxaban: Alveolar hemorrhage.
Alveolar hemorrhage (AH) is a heterogeneous clinical syndrome with a high mortality rate that is characterized by extensive bleeding into the alveolar spaces. AH usually develops secondary to immunological disease and, less frequently, to drug use. Presently described is the case of an 86-year-old woman with AH who had been using rivaroxaban for 6 months.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Obstetrics and Gynecology
سال: 2019
ISSN: 2090-6684,2090-6692
DOI: 10.1155/2019/5947153